G protein coupled receptor GPR133 / ADGRD1 agonist, preparation method and application thereof
By developing the selective GPR133 agonist AP-970/43482503, the Gs-cAMP signaling pathway is activated, and the effectiveness of vestibular dysfunction treatment and adverse androgenic reactions in the prior art has been solved, and the improvement of muscle strength and balance ability has been achieved. Effect.
Patent Information
- Application Number
- CN202410263919.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-08
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-03-08
AI Technical Summary
The existing treatment methods for vestibular dysfunction are lacking effective drugs, with a high recurrence rate, and adverse reactions to androgenic drugs, making it difficult to improve muscle strength and improve balance ability at the same time.
A selective G protein-coupled receptor GPR133 agonist AP-970/43482503 was developed to enhance muscle strength and improve balance while reducing androgen adverse reactions by activating the Gs-cAMP signaling pathway.
AP-970/43482503 significantly improves muscle strength and balance ability, has strong GPR133 agonism activity, and is used to treat or prevent muscle fragility, bone fragility and vestibular dysfunction diseases, reducing adverse reactions to androgens.
Smart Images

Figure CN118146176B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a G protein coupled receptor GPR133 / ADGRD1 agonist, a synthesis method, and applications thereof in improving skeletal muscle strength, improving balance ability, and treating or preventing muscle-related diseases and vestibular dysfunction diseases. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] The vestibular organs are located in the inner ear, including the utricle, saccule, and three semicircular canals. Sensory information from the peripheral vestibular organs, visual system, and proprioceptive system is integrated through the vestibular center of the brainstem, cerebellum, and cerebral cortex, and the body's balance and direction are maintained through the vestibular-ocular reflex (VOR) and vestibular-spinal reflex (VSR). Damage or lesions to the peripheral or central vestibular structures can lead to vestibular dysfunction (VD), that is, problems with the inner ear and brain. Clinically, peripheral vestibular lesions are mainly manifested by vertigo / dizziness, while central vestibular lesions are mainly manifested by balance dysfunction, which not only limits the patient's ability to carry out daily activities, but also increases the risk of falls, seriously affecting the patient's quality of life and social function, and increasing the patient's psychological burden and mental stress.
[0004] Vestibular dysfunction is one of the three most difficult outpatient diseases with a high clinical incidence. Survey results show that the prevalence of vestibular dysfunction in my country is 5.0-9.0%, and nearly 35% of people over 40 years old in the United States have experienced vestibular dysfunction. Among people over 65 years old, up to 30% of the elderly have a history of vertigo, and even up to 85% of the elderly over 80 years old have vestibular dysfunction. At present, the main treatment is to improve the patient's autonomic nervous function, eliminate labyrinthine water accumulation, and then improve the inner ear microcirculation. Although many studies have been conducted on vestibular dysfunction, there is no specific drug to cure the disease. Most of the drugs on the market (steroids, diuretics, etc.) are anti-motion sickness, anti-nausea drugs or middle ear injection drugs to reduce the onset of vertigo and hearing loss, but the recurrence rate is high, which is greater than 30% according to statistics. Therefore, further research in this field will help develop methods and drugs for the prevention and treatment of vestibular dysfunction.
[0005] G protein-coupled receptors (GPCRs) are a class of drug receptors that have been the most successful in the history of drug development. 30-40% of drugs used in modern clinical practice target GPCRs. There are several GPCR ligands among the world's 100 best-selling drugs, and this type of target has great potential in drug development. GPCRs are a large class of membrane receptors that can sense mechanical force. Much of their force perception is through the adhesion receptor family, and G protein-coupled receptor 133 (GPR133) is an important member of this family. GPR133 can serve as an important target for the design of drug leads and drug development targeting vertigo diseases, but no effective compounds targeting this target have been reported.
[0006] Androgens are one of the typical steroid hormones, such as 5α-dihydrotestosterone (5α-DHT), which regulates many important functions such as the expression of male secondary sexual characteristics or the development of bones and muscles. As a driver of bone and muscle formation, 5α-DHT can increase bone mineral density (BMD), enhance bone strength, and promote skeletal muscle growth to increase muscle strength. 5α-DHT not only regulates transcriptional functions by directly interacting with nuclear androgen receptors (AR), but also can induce acute physiological responses within seconds to minutes, such as regulating muscle strength, relaxing penile erectile tissue, and inducing rapid Ca in macrophages. 2+ Signal transduction and stimulation of glucose-stimulated insulin secretion in the pancreatic islets. In addition, 5α-DHT plays an important regulatory role in energy metabolism, inflammatory response, sexual function, cognitive effects, carcinogenesis, etc. However, 5α-DHT can induce a variety of adverse reactions and is associated with an increased risk of many diseases, such as androgenic alopecia, polycystic ovary syndrome, metabolic syndrome, cardiovascular disease, and prostate disease.
[0007] Screening data and cell-based reporter gene experiments showed that GPR133 can be activated by androgens, including endogenous DHT and its derivative steroid methystenolone, and has high efficacy. High-quality longevity is a human dream, but problems such as weak muscles and fragile bones are becoming a reality. Therefore, the identification of androgen membrane receptor GPR133 to increase muscle strength by sensing androgens has great potential for therapeutic applications, and the discovery of highly effective GPR133 agonists that enhance muscle strength without causing selective androgen adverse reactions is very important for a range of human diseases (such as wasting syndrome, osteoporosis or sarcopenia). Summary of the invention
[0008] An object of the present invention is to provide a compound, the general structural formula (I) of which is as follows:
[0009]
[0010] Wherein, R1 is selected from one of -OCH3, -OCH2CH3, -NHCH3 or -OCH2CH2OH;
[0011] R2 is selected from one of -CH3, -CH2CH3, -COCH3, cyclopropyl, -CH2Ph or -COPh;
[0012] R3 is selected from One of the group consisting of: R4, R5, R6, R7, and R8, each of which is independently selected from one of -H, -F, -Cl, -Br, -CH3, -OCH3, -COOH, -NO2, tert-butyl, and trifluoromethyl.
[0013] Furthermore, derivatives of the compound of general formula (I) include pharmaceutically acceptable salts, solvates, hydrates or crystals thereof.
[0014] Furthermore, the numbers and structural formulas of the specific compounds represented by general formula (I) are shown in Table 1.
[0015] Table 1 Structure of compounds of general formula (I)
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024] Another object of the present invention is to provide a method for preparing the compound of general formula (I) of the present invention, the synthetic route is as follows:
[0025]
[0026] Further, the synthesis steps are as follows:
[0027] Compound A is first subjected to amino protection to obtain intermediate B, which is then reacted with compound C under the action of a catalyst to obtain intermediate D, which is reacted with trifluoroacetic acid to obtain intermediate E, which is reacted with different carboxylic acid compounds F to obtain compounds represented by general formula (I), which is reacted with bromoacetyl bromide to obtain intermediate G, which is reacted with different compounds H to obtain compounds represented by general formula (I).
[0028] Furthermore, the synthesis steps are as follows:
[0029] Step 1: The compound of formula A and di-tert-butyl dicarbonate are heated under reflux in a solvent to protect the amino group on the benzene ring to obtain an intermediate compound of formula B;
[0030] Step 2: Dissolve the intermediate compound of formula B in a solvent, add piperazine compound C, tris(dibenzylideneacetone)dipalladium, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, and cesium carbonate in sequence, and heat under reflux under nitrogen protection to obtain an intermediate compound of formula D;
[0031] Step 3: dissolving the intermediate compound of formula D, adding trifluoroacetic acid under ice bath, and stirring at room temperature to obtain the intermediate compound of formula E;
[0032] Step 4: different carboxylic acid compounds F are dissolved, and reacted with the intermediate compound of formula E under the conditions of base DIPEA and condensation agent HATU through amide condensation reaction to obtain the compound of general formula (I);
[0033] Step 5: The intermediate compound of formula E and bromoacetyl bromide are dissolved in a solvent and reacted under the catalysis of triethylamine to obtain the intermediate compound of formula G;
[0034] Step 6: Dissolve the intermediate compound G and the phenol compound H, and react at room temperature under the catalysis of potassium carbonate to obtain the compound of general formula (I).
[0035] In response to the deficiencies mentioned in the background technology, the inventors found in previous studies that GPR133 / ADGRD1 receptors are expressed in the vestibular system of mice, and based on the study that GPR133 / ADGRD1 knockout mice exhibit vestibular dysfunction, they found through in vitro GloSensor assay in HEK293 cells that compound AP-970 / 43482503 (abbreviated as AP-970 or AP-503) can activate the Gs-cAMP signaling pathway downstream of GPR133 / ADGRD1.
[0036]
[0037] Another object of the present invention is to use the cryo-EM structure of the 5α-DHT-GPR133-Gs complex as a template, and the inventors rationally designed forward and reverse screening strategies to find that compound AP-970 / 43482503 (abbreviated as AP-503) is an effective, selective, AR-inactive GPR133 agonist. The agonist AP-503 selectively activates the Gs pathway of GPR133, EC 50 The concentration of AP-503 in the aGPCR is 1.21±0.06nM. As far as the inventors know, this is the most effective synthetic agonist developed for aGPCR so far. Moreover, the derivatives of AP-503 obtained by the inventors through structural modification based on the structure of AP-503 also showed strong GPR133 agonist activity. In addition, the inventors found that compared with 5α-DHT, AP-503 retained the muscle strengthening effect by activating GPR133 and improved certain androgen adverse reactions.
[0038] Another object of the present invention is the use of the compound of the present invention as a GPR133 / ADGRD1 agonist, and further, the use of the compound of the present invention in the preparation of a GPR133 / ADGRD1 agonist drug. The inventors have experimentally demonstrated that the compound of the present invention can activate the GPR133 / ADGRD1 downstream Gs-cAMP signaling pathway as a G protein coupled receptor 133 (GPR133) / ADGRD1 agonist.
[0039] Further, the compounds of the present invention are used in improving balance ability. The compounds of the present invention are used in preparing drugs for improving balance ability and related diseases.
[0040] Further, the compounds of the present invention are used in the prevention and / or treatment of vestibular dysfunction diseases. The compounds of the present invention are used in the preparation of drugs for the prevention and / or treatment of vestibular dysfunction diseases.
[0041] Furthermore, the compound of the present invention is used in the preparation of a drug for improving muscle strength. Furthermore, the drug for improving muscle strength can be a muscle-building drug, or a drug for preventing or treating muscle atrophy, muscle fragility, or bone fragility.
[0042] Beneficial effects:
[0043] 1. The present invention provides a small molecule compound targeting the G protein coupled receptor GPR133. The compound is disclosed for the first time. This type of compound can significantly strengthen muscles and is used to treat or prevent muscle weakness, bone weakness and other related diseases.
[0044] 2. The compounds of the present invention have excellent GPR133 agonist activity, especially the application of compound AP-970 / 43482503 in vestibular function, and can be used to prepare drugs for preventing and / or treating vestibular dysfunction diseases and improving and / or enhancing balance ability.
[0045] 3. The GPR133 agonist AP-970 / 43482503 of the present invention retains the muscle strengthening effect by activating GPR133, but improves certain adverse reactions of androgens, and has great application potential for the treatment or prevention of muscle fragility, bone fragility and other related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0047] Figure 1 The activation activity of compound AP-970 / 43482503 on GPR133 / ADGRD1 in the examples;
[0048] Figure 2 In the examples, the compound AP-970 / 43482503 was used to prevent or / and treat vestibular dysfunction diseases and improve or / and enhance balance ability through rotarod and VOR experiments;
[0049] Figure 3 8-week-old WT and Gpr133 - / - Changes in endogenous cAMP levels in the EDL after mice were treated with control or AP-503 (2 mg / kg, intramuscularly) for 30 min without the addition of the AR antagonist ORM-15341 (10 mg / kg) (14 mice per group, 7 males and 7 females);
[0050] Figure 4 For 8-week-old WT or Gpr133 - / - The latency to fall of mice in the hanging test without or with NF449 (10 mg / kg) was quantitatively analyzed with control drugs or AP-503 for 30 min (n = 14 mice per group, including 7 male mice and 7 female mice);
[0051] Figure 5 8-week-old WT and Gpr133 - / - The grip strength of mice was quantified in the grip strength test 30 minutes after administration of control drugs or AP-503 without or with NF449 (10 mg / kg) (14 mice per group, including 7 male mice and 7 female mice). DETAILED DESCRIPTION
[0052] The following is a detailed description of an embodiment of the present invention. This embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation method and a specific operation process are given, but the protection scope of the present invention is not limited to the following embodiment.
[0053] Example 1: Preparation of methyl 3-(2-(2,4-dimethylphenoxy)acetylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-503)
[0054]
[0055] Preparation of compound of formula 2:
[0056]
[0057] 3-Amino-4-bromobenzoic acid methyl ester 1 (1.0 equiv.) was dissolved in 30 mL of methanol, di-tert-butyl dicarbonate (5.0 equiv.) was added, and the mixture was refluxed at 70° C. The reaction was monitored by TLC after 12 h. After the reaction was completed, the methanol was removed under reduced pressure and the mixture was purified by silica gel (200-300 mesh) column chromatography to obtain a compound of formula 2.
[0058] Preparation of compound of formula 4:
[0059]
[0060] Take a 25 mL round-bottom flask, add compound 2 (1.0 equiv.), dissolve it with 8 mL of toluene, and add N-ethylpiperazine 3 (2.0 equiv.), tris(dibenzylideneacetone)dipalladium (0.03 equiv.), 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (2.0 equiv.), cesium carbonate (2.5 equiv.) in sequence, seal the reaction system with nitrogen, reflux at 110° C. for 12 h, after the reaction is completed, filter the insoluble salt, spin dry the filtrate, and purify it by silica gel (200-300 mesh) column chromatography to obtain a compound of formula 4.
[0061] Preparation of compound of formula 5:
[0062]
[0063] Compound 4 (1.38 equiv.) was dissolved in 3 mL of dichloromethane, trifluoroacetic acid (1 mL) was added at 0°C, and the mixture was stirred at room temperature for 2 h. After the reaction, the pH was adjusted to alkaline with saturated sodium bicarbonate solution, and the mixture was extracted with dichloromethane. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and dried, and purified by silica gel column chromatography to obtain compound 5.
[0064] Preparation of compound AP-503:
[0065]
[0066] Compound 2,4-dimethylphenoxyacetic acid 6 (1.5 equiv.) was dissolved in 2 mL N,N-dimethylformamide, and N,N-diisopropylethylamine (DIPEA, 1.1 equiv.) was added and stirred for 5 min, then N,N,N′,N′-tetramethyl-O-(7-azabenzotriazole-1-yl)urea hexafluorophosphate (HATU, 1.1 equiv.) was added and stirred for 10 min, and finally compound 5 (1.0 equiv.) was added and reacted at 60°C for 8 h. After completion, the mixture was extracted with ethyl acetate and water, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and dried, and purified by column chromatography to obtain compound AP-503 as a brown oil with a yield of 68.6%. 1 H NMR(600MHz, CDCl3) δ9.20(brs,1H),9.05(d,J=1.9Hz,1H),7.81(dd,J=8.3,2 .0Hz,1H),7.17(d,J=8.3Hz,1H),7.02(brs,1H),6.95(d,J=9.0Hz,1H),6.73(d ,J=8.3Hz,1H),4.67(s,2H),3.91(s,3H),2.91(s,4H),2.51(dd,J=14.5,7.2Hz ,2H),2.36(s,3H),2.27(s,3H),2.24(d,J=22.6Hz,4H),1.12(t,J=7.3Hz,3H).
[0067] Example 2: Preparation of 3-(2-((2-(4-ethylpiperazin-1-yl)-5-(methoxycarbonyl)phenyl)amino)-2-oxoethoxy)-5-methylbenzoic acid (AP-A-7)
[0068]
[0069] Preparation of compound of formula 7:
[0070]
[0071] In a vial, bromoacetyl bromide (1 equiv.) was dissolved in 10 mL of dichloromethane. In another vial, compound 5 (1 equiv.) and Et3N (1 equiv.) were dissolved in 10 mL of dichloromethane. The two reaction mixtures were stirred in an ice bath for 5 min. The second mixed solution was added dropwise to the first bromoacetyl bromide solution at 0°C, stirred from 0°C to room temperature for 12 h, and the solution was poured into an ice bath. The aqueous layer was extracted with dichloromethane, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and dried, and purified by silica gel column chromatography to obtain compound 7.
[0072]
[0073] Preparation of compound AP-A-7:
[0074] Compound 8 (3-hydroxy-5-methylbenzoic acid, 1.05 equiv.), compound 7 (1.0 equiv.) and potassium carbonate (3.0 equiv.) were dissolved in N,N-dimethylformamide (1.5 mL / mmol), and the mixture was stirred at room temperature for 4 hours. After the reaction was completed as determined by TLC, the mixture was extracted with dichloromethane and water. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The crude product was then recrystallized from ethanol to obtain compound AP-A-7 as a light yellow solid with a purity of 98.44%. 1 HNMR(400MHz, DMSO-d6)δ9.38(s,1H),8.85(d,J=1.9Hz,1H),7.72(dd,J=8.3,2.0Hz,1H),7.45(s,2H),7.34(d,J=8.4Hz,1H),7.20(s ,1H),4.81(s,2H),3.84(s,3H),3.32(s,4H),2.86(t,J=4.5Hz,4H),2.41(dd,J=14.5,7.3Hz,2H),2.36(s,3H),1.01(t,J=7.2Hz,3H).
[0075] Example 3: Preparation of 2-hydroxyethyl 3-(2-(3,5-dimethylphenoxy)acetylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-A-10)
[0076]
[0077] Preparation of compound of formula 10:
[0078]
[0079] The compound of formula 9 was prepared in the same manner as in Example 1, except that compound 6 was replaced with an equimolar amount of 3,5-dimethylphenoxyacetic acid. The raw material 9 was dissolved in a mixed solvent of THF:H2O=1:1, and lithium hydroxide (5 equiv.) was added while stirring at room temperature. After the reaction was completed by TLC detection, the pH was adjusted to acidic (about 3) with 1M HCl, and ethyl acetate and water were added for extraction three times. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by column chromatography to obtain compound 10.
[0080] Preparation of compound AP-A-10:
[0081]
[0082] Compound 10 (1.0 equiv.) was dissolved in dichloromethane, and thionyl chloride solution (1.5 equiv.) was added dropwise. After the addition was complete, the mixture was refluxed at 70°C for 2 h. After the reaction was completed as monitored by TLC, the mixture was returned to room temperature, the solvent was dried by rotary evaporation, and the residue 11 was directly used in the next step.
[0083] Ethylene glycol (1.0 equiv.) was dissolved in anhydrous pyridine, triethylamine (5.0 equiv.) was added at room temperature under nitrogen protection, compound 11 (4.5 equiv.) was dissolved in anhydrous dichloromethane, and slowly added dropwise to the reaction system, and the temperature was raised to 60°C and the reaction was continued for 4 hours. TLC monitored the completion of the reaction, and water was used for quenching. After the reaction returned to room temperature, 4M hydrochloric acid was added to adjust the pH to 1, and ethyl acetate was used for extraction. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the solvent was dried by spin drying. Compound AP-A-10 was separated and purified by column chromatography as a yellow solid with a purity of 99.76%. 1 H NMR(400MHz, CDCl3)δ9.46(s,1H),9.09(d,J=2.0Hz,1H),7.84(dd,J=8.3,2.0Hz,1H),7.21(d,J=8.3Hz,1H),6.70(s,1H),6.66(s,2H), 4.63(s,2H),4.46(dd,J=5.4,3.8Hz,2H),3.96(s,2H),2.93(s,4H),2.58(s,2H),2.55–2.46(m,4H),2.31(s,6H),1.14(t,J=7.2Hz,3H).
[0084] Example 4: Preparation of 3-(2-(3,5-dimethylphenoxy)acetylamino)-4-(4-ethylpiperazin-1-yl)-N-methylbenzamide (AP-A-11)
[0085]
[0086] Compound 10 (1.5 equiv.) was dissolved in 2 mL of N,N-dimethylformamide, and N,N-diisopropylethylamine (DIPEA, 1.1 equiv.) was added and stirred for 5 min. Then, N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate (HATU, 1.1 equiv.) was added and stirred for 10 min. Finally, methylamine (1.0 equiv.) was added and reacted at 60°C for 8 h. After completion, the mixture was extracted with ethyl acetate and water. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and dried, and purified by column chromatography to obtain compound AP-A-11 as a slightly yellow solid with a purity of 99.86%. 1 H NMR (400MHz, CDCl3) δ9.60(s,1H),8.77(d,J=2.1Hz,1H),7.70(dd,J=8.3,2.1Hz,1H),7.24(d,J=8.3Hz,1H),6.70(s,1H),6.66(s,2H),6.35(s ,1H),4.62(s,2H),3.00(d,J=4.8Hz,3H),2.90(t,J=4.6Hz,4H),2.57(s,2H),2.50(dd,J=14.5,7.2Hz,4H),2.31(s,6H),1.13(t,J=7.2Hz,3H).
[0087] Example 5: Preparation of Compound of Formula 13
[0088]
[0089] 3,4,5-Trimethylphenol (1.05 equiv.), ethyl bromoacetate (1.0 equiv.) and potassium carbonate (3.0 equiv.) were dissolved in N,N-dimethylformamide, and the mixture was stirred at 60°C for 12 hours. After the reaction was completed as determined by TLC, the mixture was extracted with dichloromethane and water. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. Compound 12 was obtained by silica gel column chromatography.
[0090] Compound 12 (1.0 equiv.) was dissolved in a mixed solvent of THF:H2O=1:1, and lithium hydroxide (5 equiv.) was added with stirring at room temperature. After the reaction was completed by TLC, the pH was adjusted to acidic (about 3) with 1M HCl, and ethyl acetate and water were added for extraction three times. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by column chromatography to obtain compound 13.
[0091] Methyl 3-(2-(2-chlorophenoxy)acetylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-1)
[0092] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of o-chlorophenoxyacetic acid to obtain compound AP-1 as a brown-yellow oil with a yield of 42.8%. 1 H NMR (600MHz, CDCl3) δ9.33 (s, 1H), 9.01 (d, J = 2.0Hz, 1H), 7.83 (dd, J = 8.3, 2.0 Hz,1H),7.44(dd,J=7.9,1.6Hz,1H),7.28(dd,J=7.9,1.3Hz,1H),7.20(d,J=8 .3Hz,1H),7.03(td,J=7.7,1.3Hz,1H),6.99(dd,J=8.3,1.2Hz,1H),4.74(s,2 H),3.91(s,3H),2.94(s,4H),2.59(s,4H),2.51(s,2H),1.11(t,J=6.9Hz,3H).
[0093] Methyl 3-(2-(4-chlorophenoxy)acetamido)-4-(4-ethylpiperazin-1-yl)benzoate (AP-2)
[0094] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of p-chlorophenoxyacetic acid to obtain compound AP-2 as a slightly yellow solid with a yield of 38.9%. 1 H NMR (600MHz, CDCl3) δ9.41 (s, 1H), 9.05 (d, J = 1.8Hz, 1H), 7.83–7.81 (m, 1H), 7.33–7.30 (m, 2H), 7.21 (dd ,J=8.2,3.6Hz,1H),6.99–6.95(m,2H),4.64(s,2H),3.91(s,2H),2.94(s,5H),2.50(s,6H),1.25(s,3H).
[0095] Methyl 3-(2-(2,4-dichlorophenoxy)acetamido)-4-(4-ethylpiperazin-1-yl)benzoate (AP-3)
[0096] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 2,4-dichlorophenoxyacetic acid to obtain compound AP-3 as a brown oil with a yield of 45.3%. 1H NMR (600MHz, DMSO-d6) δ9.15(s,1H),8.75(s,1H),7.73(dd,J=8.4,2.0Hz,1H),7.68(d,J=2.6Hz,1H),7.42(dd,J=8.9,2.6Hz,1H),7 .32(d,J=8.4Hz,1H),7.26(d,J=8.9Hz,1H),4.91(s,2H),3.84(s,3H),2.89(s,4H),2.51(s,4H),2.42(s,2H),1.02(t,J=7.1Hz,3H).
[0097] Methyl 3-(2-(4-bromophenoxy)acetamido)-4-(4-ethylpiperazin-1-yl)benzoate (AP-4)
[0098] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of p-bromophenoxyacetic acid to obtain compound AP-4 as a slightly yellow solid with a yield of 38%. 1 H NMR (600MHz, DMSO-d6) δ9.29(s,1H),8.78(s,1H),7.72(dd,J=8.3,2.0Hz,1H),7.55–7.52(m,2H),7.32(d,J=8.4Hz, 1H),7.07(d,J=9.0Hz,2H),4.78(s,2H),3.84(s,3H),2.87(s,4H),2.51(s,4H),2.42(s,2H),1.03(t,J=7.1Hz,3H).
[0099] Methyl 4-(4-ethylpiperazin-1-yl)-3-(2-(4-fluorophenoxy)acetamido)benzoate (AP-5)
[0100] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of p-fluorophenoxyacetic acid to obtain compound AP-5 as a brown-yellow solid with a yield of 22.9%. 1 H NMR (600MHz, DMSO-d6) δ9.33(s,1H),8.80(s,1H),7.72(dd,J=8.3,2.0Hz,1H),7.33(d,J=8.4Hz,1H),7.22–7.18(m,2 H),7.14–7.09(m,2H),4.75(s,2H),3.84(s,3H),2.88(s,4H),2.51(s,4H),2.45–2.39(m,2H),1.03(t,J=6.6Hz,3H).
[0101] Methyl 4-(4-ethylpiperazin-1-yl)-3-(2-(3-methoxyphenoxy)acetamido)benzoate (AP-6)
[0102] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 3-methoxyphenoxyacetic acid to obtain compound AP-6 as a slightly yellow solid with a yield of 48%. 1 H NMR(600MHz,DMSO-d6)δ9.33(s,1H),8.84(d,J=1.8Hz,1H),7.72(dd,J=8.3,2.0 Hz,1H),7.33(d,J=8.4Hz,1H),7.25(t,J=8.2Hz,1H),6.67(dt,J=7.3,2.2Hz,2H ),6.62(dd,J=8.1,2.1Hz,1H),4.75(s,2H),3.84(s,3H),3.76(s,3H),2.86(t,J =4.6Hz, 4H), 2.51 (d, J = 0.7Hz, 4H), 2.37 (q, J = 7.2Hz, 2H), 1.01 (t, J = 7.2Hz, 3H).
[0103] Methyl 3-(2-(4-(tert-butyl)phenoxy)acetamido)-4-(4-ethylpiperazin-1-yl)benzoate (AP-7)
[0104] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 4-tert-butylphenoxyacetic acid to obtain compound AP-7 as slightly yellow crystals with a yield of 73.7%. 1 H NMR (600MHz, DMSO-d6) δ9.34(s,1H),8.86(s,1H),7.72(dd,J=8.3,1.8Hz,1H),7.36(d,J=8.7Hz,2H),7.33(d,J=8.3Hz,1H),7.01(d,J =8.7Hz,2H),4.72(s,1H),3.84(s,3H),2.83(t,J=4.6Hz,4H),2.45(s,4H),2.37(q,J=7.1Hz,2H),1.26(s,9H),1.01(t,J=7.2Hz,3H).
[0105] Methyl 4-(4-ethylpiperazin-1-yl)-3-(2-(4-(trifluoromethyl)phenoxy)acetamido)benzoate (AP-8)
[0106] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 2-(4-trifluoromethyl)phenoxyacetic acid to obtain compound AP-8 as a slightly yellow solid with a yield of 29.2%. 1H NMR (600MHz, DMSO-d6) δ9.32(s,1H),8.77(s,1H),7.74(d,J=9.0Hz,2H),7.73–7.72(m,1H),7.32(d,J=8.4Hz,1H),7.28(d ,J=8.6Hz,2H),4.88(s,2H),3.84(s,3H),2.86(t,J=4.6Hz,4H),2.46(s,4H),2.37(q,J=7.1Hz,2H),1.00(t,J=7.2Hz,3H).
[0107] Methyl 4-(4-ethylpiperazin-1-yl)-3-(3-(p-toluenesulfonyloxy)propylamino)benzoate (AP-9)
[0108] According to the same preparation method as Example 1, compound 6 was replaced by an equal molar amount of 3-(4-tolyloxy)propionic acid to obtain compound AP-9 as a slightly yellow solid with a yield of 40.8%. 1 H NMR (600MHz, CDCl3) δ8.95 (d, J = 1.3 Hz, 1H), 8.57 (s, 1H), 7.78 (dd, J = 8.3, 1. 9Hz,1H),7.16(d,J=8.3Hz,1H),7.08(d,J=8.3Hz,2H),6.83(d,J=8.5Hz,2H) ,4.34(t,J=5.9Hz,2H),3.88(s,3H),2.94(t,J=4.6Hz,4H),2.88(t,J=5.9Hz ,2H),2.55(s,2H),2.39(q,J=7.2Hz,2H),2.28(s,3H),1.09(t,J=7.2Hz,3H).
[0109] Methyl 4-(4-acetylpiperazin-1-yl)-3-(2-(4-fluorophenoxy)acetylamino)benzoate (AP-10)
[0110] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of p-fluorophenoxyacetic acid to obtain compound AP-10 as a yellow solid with a yield of 75.6%. 1H NMR (600MHz, CDCl3) δ9.41 (s, 1H), 9.07 (d, J = 1.7Hz, 1H), 7.83 (dd, J = 8.3, 1.6Hz, 1H), 7.16 (d, J = 8.3Hz, 1H), 7.05 (t, J = 8. 5Hz,2H),6.94–6.91(m,2H),4.64(s,2H),3.91(s,3H),3.73(s,2H),3.52–3.49(m,2H),2.86(t,J=4.9Hz,4H),2.13(s,3H).
[0111] Methyl 4-(4-acetylpiperazin-1-yl)-3-(2-(3,4-dimethylphenoxy)acetamido)benzoate (AP-11)
[0112] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of 3,4-dimethylphenoxyacetic acid to obtain compound AP-11 as a slightly yellow solid with a yield of 91.9%. 1 H NMR (600MHz, CDCl3) δ9.41(s,1H),9.07(s,1H),7.83–7.80(m,1H),7.14(dd,J=8.2,2.1Hz,1H),7.08(d,J=7.8Hz,1H),6.77(s,1H),6.70(d,J=8. 0Hz,1H),4.64(s,2H),3.91(s,3H),3.69(s,2H),3.46(s,2H),2.92(dd, J=14.5,2.0Hz,2H),2.83(s,2H),2.25(s,3H),2.21(s,3H),2.11(s,3H).
[0113] Methyl 4-(4-acetylpiperazin-1-yl)-3-(2-(3,5-dimethylphenoxy)acetamido)benzoate (AP-12)
[0114] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of 3,5-dimethylphenoxyacetic acid to obtain compound AP-12 as a yellow solid with a yield of 75.6%. 1H NMR (600MHz, CDCl3) δ9.39(s,1H),9.08(d,J=1.9Hz,1H),7.82(dd,J=8.3,1.9Hz,1H),7.14(d,J=8.3Hz,1H),6.71(s,1H ),6.59(s,2H),4.65(s,2H),3.91(s,3H),3.69(s,2H),3.47–3.44(m,2H),2.85–2.80(m,4H),2.30(s,6H),2.11(s,3H).
[0115] Methyl 4-(4-acetylpiperazin-1-yl)-3-(2-(2,4-dichlorophenoxy)acetamido)benzoate (AP-13)
[0116] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of 2,4-dichlorophenoxyacetic acid to obtain compound AP-13 as a yellow solid with a yield of 75.6%. 1 HNMR (600MHz, CDCl3) δ9.34(s,1H),8.99(d,J=1.5Hz,1H),7.84(dd,J=8.3,1.7Hz,1H),7.45(d,J=2.3Hz,1H),7.27(d,J=2.4Hz,1H),7.16(d, J=8.4Hz,1H),6.94(d,J=8.8Hz,1H),4.70(s,2H),3.91(s,3H),3.75(s,2H),3.58(d,J=4.4Hz,2H),2.88(dd,J=10.3,5.1Hz,4H),2.12(s,3H).
[0117] Methyl 4-(4-acetylpiperazin-1-yl)-3-(2-(3-methoxyphenoxy)acetamido)benzoate (AP-14)
[0118] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of 3-methoxyphenoxyacetic acid to obtain compound AP-14 as a yellow solid with a yield of 75.6%. 1HNMR (600MHz, CDCl3) δ9.40 (s, 1H), 9.07 (d, J = 1.7Hz, 1H), 7.81 (dd, J = 8.3, 1.8Hz ,1H),7.24(t,J=8.3Hz,1H),7.15(d,J=8.3Hz,1H),6.61(dd,J=8.3,2.0Hz,1H),6. 57(dd,J=8.2,2.2Hz,1H),6.53(t,J=2.2Hz,1H),4.66(s,2H),3.91(s,3H),3.79( s,3H),3.71(s,2H),3.50–3.47(m,2H),2.84(dd,J=10.9,6.4Hz,4H),2.11(s,3H).
[0119] 4-(4-acetylpiperazin-1-yl)-3-(2-(4-(tert-butyl)phenoxy)acetamido)benzoic acid methyl ester (AP-15)
[0120] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of 4-tert-butylphenoxyacetic acid to obtain compound AP-15 as a yellow solid with a yield of 75.6%. 1 HNMR(600MHz, CDCl3)δ9.45(s,1H),9.09(d,J=1.9Hz,1H),7.82(dd,J=8.3,2.0Hz,1H),7.37–7.35(m,2H),7.15(d,J=8.3Hz,1H),6.92–6. 90(m,2H),4.66(s,2H),3.91(s,3H),3.69(s,2H),3.48–3.45(m,2H),2.83(dd,J=10.8,5.9Hz,5H),2.80(s,2H),2.11(s,3H),1.30(s,9H).
[0121] Methyl 4-(4-acetylpiperazin-1-yl)-3-(2-(4-(trifluoromethyl)phenoxy)acetamido)benzoate (AP-16)
[0122] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of 2-(4-trifluoromethyl)phenoxyacetic acid to obtain compound AP-16 as a yellow solid with a yield of 75.6%. 1H NMR (600MHz, CDCl3) δ9.38(s,1H),9.07(s,1H),7.84(d,J=8.2Hz,1H),7.64(d,J=8.3Hz,2H),7.18(t,J=7.4Hz, 1H),7.07(d,J=8.3Hz,2H),4.73(s,2H),3.91(s,3H),3.75(s,2H),3.47(s,2H),2.88–2.83(m,4H),2.12(s,4H).
[0123] Methyl 4-(4-acetylpiperazin-1-yl)-3-(2-(p-toluenesulfonyloxy)acetylamino)benzoate (AP-17)
[0124] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-acetylpiperazine, and compound 6 was replaced by an equal mole of p-methylphenoxyacetic acid to obtain compound AP-17 as a slightly yellow solid with a yield of 86.9%. 1 HNMR (600MHz, CDCl3) δ9.42 (s, 1H), 9.08 (d, J = 1.7Hz, 1H), 7.82 (dd, J = 8.3, 1.8Hz, 1H), 7.14 (d, J = 8.0Hz, 3H), 6.87 (d,J=8.4Hz,2H),4.64(s,2H),3.91(s,3H),3.69(s,2H),3.46(s,2H),2.85–2.82(m,4H),2.31(s,3H),2.11(s,3H).
[0125] Methyl 3-(2-(2,4-dimethylphenoxy)acetamido)-4-(4-methylpiperazin-1-yl)benzoate (AP-18)
[0126] According to the same preparation method as Example 1, compound 3 was replaced with an equal mole of N-methylpiperazine to obtain compound AP-18 as a brown oil with a yield of 72.8%. 1 H NMR (600MHz, CDCl3) δ9.25(s,1H),9.04(d,J=1.9Hz,1H),7.81(dd,J=8.3,2.0Hz,1H),7.18(d,J=8.3Hz,1H),7.02(s,1H),6.95( d,J=8.3Hz,1H),6.73(d,J=8.3Hz,1H),4.66(s,2H),3.91(s,3H),2.85(t,J=4.7Hz,4H),2.38(s,3H),2.28(s,3H),2.26(s,3H).
[0127] Methyl 3-(2-(2,4-dibromophenoxy)propylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-19)
[0128] According to the same preparation method as Example 1, compound 6 was replaced with an equal mole of 2-(2,4-dibromophenoxy)propionic acid to obtain compound AP-19 as a slightly yellow solid with a yield of 58.6%. 1 H NMR (600MHz, CDCl3) δ9.17 (s, 1H), 8.97 (d, J = 1.7Hz, 1H), 7.81 (dd, J = 8.3, 1.8Hz, 1 H),7.73(d,J=2.3Hz,1H),7.37(dd,J=8.8,2.3Hz,1H),7.17(d,J=8.3Hz,1H),6.81( d,J=8.8Hz,1H),4.77(q,J=6.8Hz,1H),3.90(s,3H),2.88(s,2H),2.83(s,2H),2.53 (s,2H),2.45(td,J=12.5,5.2Hz,2H),1.72(d,J=6.8Hz,3H),1.09(t,J=7.2Hz,3H).
[0129] Methyl 4-(4-ethylpiperazine-1-yl)-3-(2-phenoxypropylamino)benzoate (AP-20)
[0130] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 2-phenoxypropionic acid to obtain compound AP-20 as a brown oil with a yield of 71.6%. 1 H NMR (600MHz, CDCl3) δ9.32(s,1H),9.05(d,J=1.8Hz,1H),7.79(dd,J=8.3,1.8Hz,1H),7.31(t,J=8.0Hz,2H),7.16(d,J=8.3Hz,1H),7.03(d,J=7.4Hz,1 H),7.00(d,J=8.1Hz,2H),4.80(q,J=6.8Hz,1H),3.90(s,3H),2.82(d,J=25 .7Hz,4H),2.48–2.37(m,4H),1.68(d,J=6.8Hz,3H),1.08(t,J=7.2Hz,3H).
[0131] Methyl 4-(4-ethylpiperazin-1-yl)-3-(2-(4-methoxyphenoxy)propylamino)benzoate (AP-21)
[0132] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 2-(4-methoxyphenoxy)propionic acid to obtain compound AP-21 as a brown oil with a yield of 53.4%. 1 H NMR (600MHz, CDCl3) δ9.27(s,1H),9.03(s,1H),7.79(d,J=8.3Hz,1H),7.17(d,J=8.3Hz,1H),6.93(dd,J=9.0,2.5Hz,2H),6.87–6.83(m,2H),4 .69(dd,J=13.3,6.5Hz,1H),3.90(s,3H),3.77(s,3H),2.93(s,4H),2. 80(s,3H),2.68–2.57(m,4H),1.66–1.64(m,2H),1.16(t,J=7.1Hz,3H).
[0133] Methyl 3-(2-(4-chlorophenoxy)propylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-22)
[0134] According to the same preparation method as Example 1, compound 6 was replaced by an equal molar amount of 2-(4-chlorophenoxy)propionic acid to obtain compound AP-22 as a brown oil with a yield of 64.2%. 1 H NMR (600MHz, CDCl3) δ9.26 (s, 1H), 9.03 (d, J = 1.8Hz, 1H), 7.79 (dd, J = 8.3, 1.9Hz, 1H), 7.27 (d, J = 9.0Hz, 2H), 7.17 (d, J = 8.3Hz, 1H), 6.94 (d ,J=9.0Hz,2H),4.75(q,J=6.8Hz,1H),3.90(s,3H),2.84(d,J=19.5Hz,4H),2.50–2.39(m,4H),1.67(d,J=6.8Hz,3H),1.10(t,J=7.2Hz,3H).
[0135] Methyl 3-(2-(2-chlorophenoxy)propylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-23)
[0136] According to the same preparation method as Example 1, compound 6 was replaced by an equal molar amount of 2-(2-chlorophenoxy)propionic acid to obtain compound AP-23 as a slightly yellow oil with a yield of 52.3%. 1H NMR (600MHz, CDCl3) δ9.29 (s, 1H), 9.00 (d, J = 1.6Hz, 1H), 7.80 (dd, J = 8.3, 1.6Hz, 1H ),7.42(d,J=7.9Hz,1H),7.21(t,J=7.8Hz,1H),7.16(d,J=8.3Hz,1H),6.99(t,J=7.7 Hz,1H),6.96(d,J=8.2Hz,1H),4.82(q,J=6.8Hz,1H),3.90(s,3H),2.85(d,J=14.2H z,4H),2.50(s,2H),2.45–2.40(m,2H),1.72(d,J=6.8Hz,3H),1.07(t,J=7.2Hz,3H).
[0137] Methyl 4-(4-ethylpiperazin-1-yl)-3-(2-(o-tolyloxy)propylamino)benzoate (AP-24)
[0138] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 2-(2-methylphenoxy)propionic acid to obtain compound AP-24 as a slightly yellow solid with a yield of 59.1%. 1 H NMR (600MHz, CDCl3) δ9.19 (s, 1H), 9.04 (d, J = 1.9Hz, 1H), 7.79 (dd, J = 8.3, 2.0Hz, 1H ),7.19(d,J=7.4Hz,1H),7.14(d,J=8.3Hz,1H),7.11(t,J=7.8Hz,1H),6.93(t,J=7.4 Hz,1H),6.80(d,J=8.2Hz,1H),4.74(q,J=6.8Hz,1H),3.90(s,3H),2.79(s,4H),2.3 8(s,3H),2.30(dt,J=19.3,7.1Hz,4H),1.70(d,J=6.8Hz,3H),1.04(t,J=7.2Hz,3H).
[0139] Methyl 3-(2-(3-chlorophenoxy)propylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-25)
[0140] According to the same preparation method as Example 1, compound 6 was replaced by an equal molar amount of 2-(3-chlorophenoxy)propionic acid to obtain compound AP-25 as a brown-yellow oil with a yield of 51.5%. 1H NMR (600MHz, CDCl3) δ9.27(s,1H),9.04(s,1H),7.79(d,J=8.3Hz,1H),7.23(t,J=8.2Hz,1H),7.17(d,J=8.3Hz,1H),7.06(s,1H),7.02(d,J=8.0Hz, 1H),6.86(dd,J=8.3,2.1Hz,1H),4.79(q,J=6.7Hz,1H),3.90(s,3H),2.8 5(s,4H),2.51–2.39(m,4H),1.69(d,J=6.7Hz,3H),1.11(t,J=7.2Hz,3H).
[0141] 4-(4-Benzoylpiperazin-1-yl)-3-(2-(3,5-dimethylphenoxy)acetamido)benzoic acid methyl ester (AP-A-1)
[0142] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-benzoylpiperazine, and compound 6 was replaced by an equal mole of 3,5-dimethylphenoxyacetic acid to obtain compound AP-A-1 as a slightly yellow solid with a purity of 98.36%. 1 H NMR(400MHz, DMSO-d6)δ9.33(s,1H),8.78(d,J=1.8Hz,1H),7.73(dd,J=8.3,2.0Hz,1H),7.49–7.46(m,3H),7.41–7.39(m,2H), 7.35(d,J=8.4Hz,1H),6.69(s,2H),6.65(s,1H),4.73(s,2H),3.84(s,3H),3.66(s,2H),3.28(s,2H),2.87(s,4H),2.23(s,6H).
[0143] Methyl 4-(4-benzoylpiperazin-1-yl)-3-(2-(o-tolyloxy)acetamido)benzoate (AP-A-2)
[0144] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-benzoylpiperazine, and compound 6 was replaced by an equal mole of o-methylphenoxyacetic acid to obtain compound AP-A-2 as a yellow solid with a purity of 99.58%. 1HNMR(400MHz,DMSO-d6)δ9.25(s,1H),8.75(d,J=1.8Hz,1H),7.73(dd,J=8.4,2.0Hz,1 H),7.46(dd,J=5.0,1.7Hz,3H),7.39(dd,J=6.6,3.1Hz,2H),7.34(d,J=8.4Hz,1H),7. 23(d,J=7.2Hz,1H),7.15(t,J=7.8Hz,1H),6.96(d,J=8.1Hz,1H),6.91(t,J=7.4Hz,1H ),4.80(s,2H),3.84(s,3H),3.65(s,2H),3.30–3.24(m,2H),2.86(s,4H),2.33(s,3H).
[0145] 3-(4,6-dimethylbenzofuran-2-carboxamido)-4-(4-ethylpiperazin-1-yl)benzoic acid methyl ester (AP-A-3)
[0146] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-benzoylpiperazine, and compound 6 was replaced by an equal mole of 4,6-dimethylcoumaric acid to obtain compound AP-A-3 as a brown-yellow solid with a purity of 99.08%. 1 H NMR (400MHz, CDCl3) δ9.56(s,1H),9.12(d,J=2.0Hz,1H),7.83(dd,J=8.3,2.0Hz,1H),7.60(d,J=0.9Hz,1H),7.24(d,J=8.3Hz,1H),7.14(s,1H ),6.97(s,1H),3.92(s,3H),3.06(t,J=4.4Hz,4H),2.79(s,4H),2.62(dd,J=14.0,7.0Hz,2H),2.54(s,3H),2.49(s,4H),1.21(t,J=7.2Hz,3H).
[0147] Methyl 3-(2-(3,5-dimethylphenoxy)-2-methylpropylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-A-4)
[0148] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-benzoylpiperazine, and compound 6 was replaced by an equal mole of 2-(3,5-dimethylphenoxy)-2-methyl-propionic acid to obtain compound AP-A-4 as an orange-yellow solid with a purity of 99.68%. 1H NMR (400MHz, CDCl3) δ9.57(s,1H),9.10(d,J=2.0Hz,1H),7.79(dd,J=8.3,2.0Hz,1H),7.17(d,J=8.3Hz,1H),6.70(s,1H),6. 59(s,2H),3.90(s,3H),2.85(t,J=4.3Hz,4H),2.37(dd,J=14.4,7.2Hz,4H),2.25(s,8H),1.62(s,6H),1.04(t,J=7.2Hz,3H).
[0149] Methyl 4-(4-benzylpiperazin-1-yl)-3-(2-(3,5-dimethylphenoxy)acetamido)benzoate (AP-A-5)
[0150] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-benzylpiperazine, and compound 6 was replaced by an equal mole of 3,5-dimethylphenoxyacetic acid to obtain compound AP-A-5 as a white solid with a purity of 98.64%. 1 H NMR(400MHz, DMSO-d6)δ9.35(s,1H),8.86(d,J=1.9Hz,1H),7.71(dd,J=8.3,2.0Hz,1H),7.36–7.27(m,6H),6.7 6(s,2H),6.70(s,1H),4.71(s,2H),3.84(s,3H),3.51(s,2H),2.86(t,J=4.5Hz,4H),2.49(s,4H),2.29(s,6H).
[0151] Methyl 4-(4-cyclopropylpiperazin-1-yl)-3-(2-(3,5-dimethylphenoxy)acetamido)benzoate (AP-A-6)
[0152] According to the same preparation method as Example 1, compound 3 was replaced by an equal mole of 1-cyclopropylpiperazine, and compound 6 was replaced by an equal mole of 3,5-dimethylphenoxyacetic acid to obtain compound AP-A-6 as a slightly yellow solid with a purity of 99.20%. 1H NMR (400MHz, DMSO-d6) δ9.38(s,1H),8.87(d,J=1.9Hz,1H),7.70(dd,J=8.3,2.1Hz,1H),7.31(d,J=8.4Hz,1H),6.76(s,2H),6.68(s,1H),4.72 (s,2H),3.84(s,3H),2.82–2.78(m,4H),2.67(d,J=1.8Hz,4H),2.25(s, 6H),1.65(dt,J=9.8,3.3Hz,1H),0.48–0.43(m,2H),0.35–0.30(m,2H).
[0153] 3-Chloro-5-(2-((2-(4-ethylpiperazin-1-yl)-5-(methoxycarbonyl)phenyl)amino)-2-oxoethoxy)benzoic acid (AP-A-8)
[0154] According to the same preparation method as Example 2, compound 8 was replaced by an equal molar amount of 3-chloro-5-hydroxybenzoic acid to obtain compound AP-A-8 as a brown-yellow solid with a purity of 98.87%. 1 H NMR (400MHz, DMSO-d6) δ9.38(s,1H),8.78(s,1H),7.73(dd,J=8.3,1.9Hz,1H),7.58(dd,J=6.0,1.4Hz,2H),7.46(s,1H), 7.33(d,J=8.3Hz,1H),4.89(s,2H),3.84(s,3H),2.90(s,4H),2.58(s,4H),2.46(d,J=7.1Hz,2H),1.03(t,J=7.1Hz,3H).
[0155] Methyl 3-(2-(3,5-dimethylphenoxy)propylamino)-4-(4-ethylpiperazin-1-yl)benzoate (AP-A-9)
[0156] According to the same preparation method as Example 1, compound 6 was replaced by an equal mole of 2-(3,5-dimethylphenoxy)propionic acid to obtain compound AP-A-9 as a light yellow solid with a purity of 96.50%. 1H NMR (400MHz, DMSO-d6) δ9.31(s,1H),8.80(d,J=2.0Hz,1H),7.70(dd,J=8.3,2.1Hz,1H),7.30(d,J=8.4Hz,1H),6.69(s,2H),6.66(s,1H),4. 98(q,J=6.6Hz,1H),3.84(s,3H),2.79(dt,J=12.1,6.1Hz,4H),2.43–2.29(m,6H),2.23(s,6H),1.53(d,J=6.7Hz,3H),1.00(t,J=7.2Hz,3H).
[0157] 4-(4-Benzoylpiperazin-1-yl)-3-(2-(3,5-dimethylphenoxy)acetamido)benzoic acid ethyl ester (AP-A-12)
[0158] According to the same preparation method as Example 1, compound 1 was replaced with an equal molar amount of ethyl 3-amino-4-bromobenzoate, compound 3 was replaced with an equal molar amount of 1-benzoylpiperazine, and compound 6 was replaced with an equal molar amount of 3,5-dimethylphenoxyacetic acid to obtain compound AP-A-12 as a white solid with a purity of 99.63%. 1 H NMR (400MHz, DMSO-d6) δ9.33(s,1H),8.77(d,J=1.8Hz,1H),7.72(dd,J=8.3,2.0Hz,1H),7.47(dd,J=5.0,1.7Hz,3H),7.42–7.39(m,2H),7.34 (d,J=8.4Hz,1H),6.69(s,2H),6.64(s,1H),4.73(s,2H),4.30(q,J=7.1Hz,2H),3.68(s,4H),2.87(s,4H),2.23(s,6H),1.31(t,J=7.1Hz,3H).
[0159] Methyl 4-(4-ethylpiperazin-1-yl)-3-(2-(3-methyl-5-nitrophenoxy)acetamido)benzoate (AP-A-13)
[0160] According to the same preparation method as Example 2, compound 8 was replaced by an equal molar amount of 3-methyl-5-nitrophenol to obtain compound AP-A-13 as a white solid with a purity of 99.62%. 1H NMR(400MHz, CDCl3)δ9.50(s,1H),9.07(d,J=1.9Hz,1H),7.83(dd,J=8.3,2.0Hz,1H),7.78–7.73(m,2H),7.24(d,J=8.3Hz,1H),7.17( s,2H),4.72(s,2H),3.91(s,3H),2.96(t,J=4.5Hz,4H),2.64(s,2H),2.53(dd,J=14.3,7.1Hz,4H),2.48(s,3H),1.14(t,J=7.2Hz,3H).
[0161] 3-(4-(3,5-dimethylphenoxy)butyrylamino)-4-(4-ethylpiperazin-1-yl)benzoic acid methyl ester (AP-A-14)
[0162] According to the same preparation method as Example 1, compound 6 was replaced by an equal molar amount of 3,5-dimethylphenoxybutyric acid to obtain compound AP-A-14 as a slightly yellow solid with a purity of 99.57%. 1 H NMR (400MHz, CDCl3) δ8.97(s,1H),8.27(s,1H),7.77(dd,J=8.3,2.0Hz,1H),7.17(d,J=8.3Hz,1H),6.58(s,1H),6.51(s,2H),4.03(t,J=5.7H z,2H),3.89(s,3H),2.92(s,4H),2.63(t,J=7.0Hz,6H),2.50(dd,J=14.3,7.1Hz,2H),2.26(s,6H),2.25–2.20(m,2H),1.14(t,J=7.2Hz,3H).
[0163] 4-(4-ethylpiperazin-1-yl)-3-(2-(3,4,5-trimethylphenoxy)acetamido)benzoic acid methyl ester (AP-A-15)
[0164] The compound of formula 5 and the compound of formula 13 were prepared by condensation reaction in the same manner as in Example 1 to obtain compound AP-A-15, a light yellow solid with a purity of 99.49%. 1H NMR (400MHz, CDCl3) δ9.46(s,1H),9.07(d,J=2.0Hz,1H),7.81(dd,J=8.3,2.0Hz,1H),7.19(d,J=8.3Hz,1H),6.70(s,2H),4.62( s,2H),3.90(s,3H),2.92(t,J=4.7Hz,4H),2.56(s,2H),2.49(q,J=7.2Hz,4H),2.28(s,6H),2.12(s,3H),1.12(t,J=7.2Hz,3H).
[0165] Methyl 4-(4-ethylpiperazin-1-yl)-3-(2-(3-methoxy-5-methylphenoxy)acetamido)benzoate (AP-A-16)
[0166] The same preparation method as compound AP-A-15 was used to replace 3,4,5-trimethylphenol with an equal mole of 3-methoxy-5-methylphenol. White solid with a purity of 99.29%. 1 H NMR (400MHz, CDCl3) δ9.43(s,1H),9.07(d,J=2.0Hz,1H),7.81(dd,J=8.3,2.0Hz,1H),7.20(d,J=8.3Hz,1H),6.48–6.38(m,3H),4. 63(s,2H),3.91(s,3H),3.79(s,3H),2.92(t,J=4.7Hz,4H),2.56(s,2H),2.48(q,J=7.2Hz,4H),2.32(s,3H),1.12(t,J=7.2Hz,3H).
[0167] Example 6: Compound AP-970 / 43482503's ability to activate GPR133 / ADGRD1
[0168] The stock solution of the test compound (dissolved in DMSO) was prepared with HBSS to a working concentration of 10 -11 M, 10 -10 M, 10 -9 M, 10 - 8 M, 10 -7 M, 10 -6 M, 10 -5 M, 10 -4 M, in HEK293 cells overexpressing GPR133 / ADGRD1 and G protein, different concentrations (10 -11 -10 -4M) were used as the negative control, and HEK293 cells expressing the empty vector pcDNA3.1 were used as the negative control. The fluorescence value was recorded in real time using a multifunctional microplate reader, and the results were statistically analyzed and plotted. Figure 1 The experimental results showed that compound AP-970 / 43482503 (abbreviated as AP-503 or AP-970) can activate the Gs-cAMP signaling pathway downstream of GPR133 / ADGRD1, EC 50 The agonistic activity of other AP-503 derivatives on GPR133 is shown in Table 1 below.
[0169] Table 1 Agonist activity of compounds on GPR133
[0170] Compounds <![CDATA[EC 50 (nM)]]> Compounds <![CDATA[EC 50 (nM)]]> Compounds <![CDATA[EC 50 (nM)]]> AP-503 1.21±0.06 AP-14 5.42±0.12 AP-A-3 2.46±0.55 AP-1 5.32±0.12 AP-15 1.01±0.04 AP-A-4 5.36±0.38 AP-2 11.25±0.24 AP-16 15.52±1.34 AP-A-5 4.21±0.24 AP-3 12.41±0.26 AP-17 7.36±0.14 AP-A-6 8.06±0.36 AP-4 21.23±0.67 AP-18 41.35±3.86 AP-A-7 9.26±0.34 AP-5 31.21±0.96 AP-19 40.06±3.81 AP-A-8 7.02±0.16 AP-6 22.11±0.84 AP-20 3.01±0.04 AP-A-9 9.82±0.40 AP-7 6.21±0.12 AP-21 51.71±4.06 AP-A-10 8.21±0.38 AP-8 11.32±0.22 AP-22 12.26±0.36 AP-A-11 22.67±0.96 AP-9 21.03±1.56 AP-23 11.21±0.34 AP-A-12 30.64±1.36 AP-10 4.01±0.80 AP-24 6.38±0.29 AP-A-13 26.40±1.26 AP-11 6.39±0.14 AP-25 3.03±0.18 AP-A-14 20.52±1.45 AP-12 21.21±2.44 AP-A-1 2.54±0.09 AP-A-15 3.06±0.23 AP-13 3.31±0.07 AP-A-2 6.80±0.36 AP-A-16 5.21±0.30
[0171] Example 7: Effects of compound AP-970 / 43482503 on balance function and vestibular dysfunction
[0172] 8-week-old male WT and Adgrd1 C57BL / 6J - / - Mice were randomly divided into groups and given 6 μg / (kg·d) vasopressin acetate intraperitoneally for 10 days and 0.1 mg / (kg·d) aldosterone intraperitoneally for 5 days to establish vestibular dysfunction models. At the same time, 1 mg / kg compound AP-970 was given intraperitoneally. The time mice stayed on the rotating rod at 8 rpm within 3 minutes was measured, and the results were statistically analyzed and plotted. The results are shown in Figure 2 At the same time, the vestibular ocular reflex (VOR) experiment of mice was tested, and the Gain value (1.0 Hz) of the results was statistically analyzed and plotted. The results are shown in Figure 2 The experimental results showed that the vestibular balance function of mice was significantly impaired after vasopressin acetate (VP) and aldosterone (ALD) modeling; compound AP-970 can improve the vestibular balance dysfunction of mice by activating GPR133 / ADGRD1 receptors, and can even improve or / and normal vestibular balance function of mice. The effects of other AP-503 derivatives on vestibular balance function are shown in Table 2 below.
[0173] Table 2 Effects of compounds on vestibular balance function
[0174]
[0175]
[0176] Example 8: Effect of compound AP-970 / 43482503 on cAMP levels in mouse skeletal muscle
[0177] The effects of AP-503 on cAMP production and muscle strength in the extensor digitorum longus (EDL) of mice were detected by ELISA kit. Compared with DHT treatment, AP-503 treatment in the EDL of female and male mice for 30 minutes significantly increased cAMP levels and rapidly increased skeletal muscle strength, while pre-incubation with the AR antagonist ORM-15341 had no effect. The results are shown in Figure 3 .
[0178] Example 9: Effect of compound AP-970 / 43482503 on the hanging time of mice
[0179] WT or Gpr133 - / - The mice were placed on a wire platform, which was then inverted and suspended 750 mm above a landing box filled with cotton and sawdust to prevent the mice from any potential injury. The time it took for the mice to fall from the inverted platform was recorded (maximum 60 seconds each time). The mice underwent three consecutive trials with a 5-minute rest period between each trial. The average residence time of the three trials was used for analysis, and the results are shown in Figure 4 .
[0180] Example 10: Effect of compound AP-970 / 43482503 on the gripping power of mice
[0181] The muscle grip strength of mice was measured using an automated grip strength meter (Bioseb). - / - The mouse held its front paws with its tail and placed its hind paws on the mesh. The mouse's tail was gently pulled at a speed of 2-3 cm / s, and the maximum grip force was recorded. Each mouse was divided into 5 consecutive tests, with a 5-minute rest between each test. The average grip strength of the three highest readings was used for analysis. The results are shown in Figure 5 .
[0182] Through the two behavioral experiments of the suspension test to record the falling time of mice and the gripping test to record the gripping strength of mice, it is further proved that the DHT analog AP-503 (30 minutes of intramuscular injection stimulation) can quickly increase muscle strength by activating GPR133. It can be used as a muscle-building drug, and can also be further developed as a drug to prevent or treat muscle atrophy, muscle fragility, and bone fragility.
[0183] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A compound, whose general structural formula (I) is as follows: Its characteristics are: The numbers and structural formulas of the specific compounds represented by general formula (I) are as follows:
2. The method for preparing the compound according to claim 1, characterized in that: The synthetic route is as follows:
3. The preparation method according to claim 2, characterized in that: The synthesis steps are as follows: Compound A is first subjected to amino protection to obtain intermediate B, which is then reacted with compound C under the action of a catalyst to obtain intermediate D, which is reacted with trifluoroacetic acid to obtain intermediate E, which is reacted with different carboxylic acid compounds F to obtain the compound represented by general formula (I), or E is reacted with bromoacetyl bromide to obtain intermediate G, which is reacted with different compounds H to obtain the compound represented by general formula (I).
4. The preparation method according to claim 2, characterized in that: The detailed synthesis steps are as follows: Step 1: The compound of formula A and di-tert-butyl dicarbonate are heated under reflux in a solvent to protect the amino group on the benzene ring to obtain an intermediate compound of formula B; Step 2: Dissolve the intermediate compound of formula B in a solvent, add piperazine compound C, tris(dibenzylideneacetone)dipalladium, 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl, and cesium carbonate in sequence, and heat under reflux under nitrogen protection to obtain an intermediate compound of formula D; Step 3: dissolving the intermediate compound of formula D, adding trifluoroacetic acid under ice bath, and stirring at room temperature to obtain the intermediate compound of formula E; Step 4: different carboxylic acid compounds F are dissolved, and reacted with the intermediate compound of formula E under the conditions of base DIPEA and condensation agent HATU through amide condensation reaction to obtain the compound of general formula (I); Alternatively: the intermediate compound of formula E and bromoacetyl bromide are dissolved in a solvent, and reacted under the catalysis of triethylamine to obtain the intermediate compound of formula G; the intermediate compound of formula G and the phenol compound H are dissolved, and reacted at room temperature under the catalysis of potassium carbonate to obtain the compound of general formula (I).
5. Use of a compound as a GPR133 / ADGRD1 agonist, characterized in that the compound The general structural formula (I) is as follows: Wherein, R1 is selected from one of -OCH3, -OCH2CH3, -NHCH3 or -OCH2CH2OH; R2 is selected from one of -CH3, -CH2CH3, -COCH3, cyclopropyl, -CH2Ph or -COPh; R3 is selected from One of the group consisting of: R4, R5, R6, R7, and R8, each of which is independently selected from one of -H, -F, -Cl, -Br, -CH3, -OCH3, -COOH, -NO2, tert-butyl, and trifluoromethyl.
6. The use according to claim 5, characterized in that: The compound activates the Gs-cAMP signaling pathway downstream of GPR133 / ADGRD1 and exerts an agonistic effect.
7. Use of a compound in the preparation of a drug for improving balance ability and treating related diseases, characterized in that the compound The general structural formula (I) is as follows: Wherein, R1 is selected from one of -OCH3, -OCH2CH3, -NHCH3 or -OCH2CH2OH; R2 is selected from one of -CH3, -CH2CH3, -COCH3, cyclopropyl, -CH2Ph or -COPh; R3 is selected from One of the group consisting of: R4, R5, R6, R7, and R8, each of which is independently selected from one of -H, -F, -Cl, -Br, -CH3, -OCH3, -COOH, -NO2, tert-butyl, and trifluoromethyl.
8. Use of a compound in the preparation of a drug for preventing and / or treating vestibular dysfunction, characterized in that the compound The general structural formula (I) is as follows: Wherein, R1 is selected from one of -OCH3, -OCH2CH3, -NHCH3 or -OCH2CH2OH; R2 is selected from one of -CH3, -CH2CH3, -COCH3, cyclopropyl, -CH2Ph or -COPh; R3 is selected from One of the group consisting of: R4, R5, R6, R7, and R8, each of which is independently selected from one of -H, -F, -Cl, -Br, -CH3, -OCH3, -COOH, -NO2, tert-butyl, and trifluoromethyl.
9. Use of a compound in the preparation of a drug for improving muscle strength, characterized in that the compound The general structural formula (I) is as follows: Wherein, R1 is selected from one of -OCH3, -OCH2CH3, -NHCH3 or -OCH2CH2OH; R2 is selected from one of -CH3, -CH2CH3, -COCH3, cyclopropyl, -CH2Ph or -COPh; R3 is selected from One of the group consisting of: R4, R5, R6, R7, and R8, each of which is independently selected from one of -H, -F, -Cl, -Br, -CH3, -OCH3, -COOH, -NO2, tert-butyl, and trifluoromethyl.
Citation Information
Cited By
G protein coupled receptor GPR133 / ADGRD1 agonist, preparation method and application thereof
CN121698826A
